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Risk Factors and Molecular 
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Kyungwon Lee4
Due to the spread of a single CTX-M-type extended-spectrum β-lactamase (ESBL) clone of sequence 
type (ST) 131, community-onset bacteremia caused by ESBL-producing Escherichia coli has increased 
dramatically. We evaluated the risk factors and molecular features of ESBL-producing E. coli ST131 
clones isolated from Korean patients with community-onset bacteremia. We collected a total of 124 
ESBL-producing E. coli isolates from blood in patients with community-onset bacteremia over a 2 year-
period. Among 124 patients, the number of community-associated bacteremia cases was 57 (46%). 
ST131 strains accounted for 49.1% (28/57) of community-associated bacteremia cases and 44.8% 
(30/67) of healthcare-associated community-onset bacteremia cases. Among 58 ST131 strains, nine 
isolates were shown to harbor O16-H41, and 61.1% (30/49) of O25 had H30Rx. In a multivariate analysis, 
independent risk factors for acquisition of ST131 isolates over non-ST131 isolates were underlying 
diabetes mellitus and absence of prior chemotherapy history. The most common ESBL genotype was 
CTX-M-15 (46.0%), followed by CTX-M-14 (37.1%). A considerable proportion of community-onset 
ESBL-producing E. coli bacteremia was observed. ST131 clones appear to be associated with the spread 
of community-associated bacteremia exhibiting high antimicrobial resistance and highly virulent H30Rx 
traits, which could become a major public health concern in Korea.
Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli has become widespread in hospitals around 
the world since the late 1980s1, but the sudden worldwide increase in communities is mainly due to CTX-M-type 
ESBLs (especially CTX-M-15)-producing sequence type (ST) 1312,3. The most common type of infection by 
ESBL-producing E. coli is urinary tract infection with good clinical outcomes4,5. Life-threatening infections such 
as bacteremia have not drawn public attention until now, but the emergence of community-onset bacteremia by 
ESBL-producing E. coli ST131 clones in Korea has been a concern in recent reports6–8. ST131 ESBL-producing 
E. coli from bacteremia cases possessed more virulence traits and showed more multidrug resistance patterns 
than non-ST131 isolates7. Recent molecular epidemiology showed that H30Rx subsets within ST131-O25-H30 
subclones were associated specifically with fluoroquinolone resistance, and CTX-M-15 was widely detected in 
Korea (37% of total ST131 isolates)8. Risk factors of community-onset bacteremia by E. coli through a compari-
son of ESBL and non-ESBL groups have already been evaluated9, but the clinical impacts of ST131 have not been 
elucidated in community-onset bacteremia as far as we know. The potential spread of ESBL-producing E. coli 
causing blood stream infections is a challenge for the management of community-associated infections, so this 
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study could be informative regarding current molecular epidemiologic shifts in community-onset bacteremia and 
could lead to better infection control strategies.
Methods
Design and Setting. We collected 124 non-duplicated (except initial isolate from each patient duplicate 
series) ESBL-producing E. coli blood culture isolates from consecutively encountered patients with communi-
ty-onset bacteremia, as outpatients or within 48 hours of admission between 2013 and 2014 in Severance hospital, 
which is one one tertiary teaching hospital in Seoul, Korea. Community-associated bacteremia, risk factors, asso-
ciated disease, and source of infection followed the definitions used in our previous study9. Briefly, healthcare-as-
sociated infections were classified in accordance to the definition by Friedman et al. with some modifications10. 
Any of the following criteria were considered as healthcare-associated infections: intravenous therapy, wound 
care, or nursing care received at home 30 days before bloodstream infection; attendance at a hospital or hemodi-
alysis clinic, or receipt of intravenous chemotherapy 30 days before bloodstream infection; >48 hours of hospital 
admission or performance of invasive procedures such as urinary catheter, endoscopy, and naso-gastric tube 90 
days before bloodstream infection; or residence at nursing home or long-term care facility. Thirty-day mortality 
was defined as death for any reason within 30 days after the onset of the bacteremia. Immunosuppression was 
defined as follows: therapy of prednisolone or an equivalent drug with a dosage of at least 10 mg/day for 15 days, 
and chemotherapy or radiotherapy within 6 months before the bacteremia11.
Microbiological Analysis. Identification, ESBL screening, and susceptibility testing were performed using 
the automated analyzer Vitek 2 system (bioMérieux, Marcy l′E’toile, France), and results of susceptibility were 
interpreted using the CLSI12. For detection of ST131, all isolates were screened via PCR for O16-ST131 and 
O25-ST13113. FimH type and H30Rx were determined using PCR and sequencing14,15. ESBL genotypes were 
determined via PCR and sequencing16. Sequence types (ST) were confirmed with full multilocus sequence typing 
(MLST) for representative isolates of community-associated bacteremia group17,18. Pulsed-field gel electropho-
resis (PFGE) was performed as described in our previous study9. The patterns were analyzed using InfoQuest FP 
software (Bio-Rad) to generate a dendrogram based on the unweighted pair group method, with an arithmetic 
average (UPGMA) from the Dice coefficient with 1% band position tolerance and 0.5% optimization settings. A 
PCR-based replicon typing (PBRT) was schemed by targeting the replicons of major plasmid families occurring 
Figure 1. Pulsed-field gel electrophoresis (PFGE) of XbaI-restricted DNA of 120 community-onset ESBL-
producing E. coli: (A) 56 community-associated ESBL-producing E. coli; (B) 64 healthcare-associated ESBL-
producing E. coli.
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in Enterobacteriaceae (HI2, HI1, I1-γ, X, L/M, N, FIA, FIB, FIC, W, Y, P, A/C, T, K, B/O) for representative 
isolates19.
Statistical Analysis. Continuous variable, such as age, was analyzed by using the Mann-Whitney U test. The 
chi-squared test was used for the comparative analysis of categorical variables in order to determine independent 
risk factors. Odds ratio (OR) and 95% confidence interval (CI) values were calculated for binomial variables. 
Variables for which the P values were less than 0.1 in univariate analyses were included in a multivariate logistic 
regression analysis model to determine independent risk factors for acquisition of ST131 isolates. Statistical sig-
nificance was defined as P < 0.05. SPSS 17.0 software (SPSS, Chicago, IL, USA) was used for univariate analyses 
and multivariate analyses.
Data Availability. All data generated or analysed during this study are included in this published article.
Clinical features CA (n = 57) HA (n = 67) OR (95% CI) P value
Age in years, median (IQR) 72.0 (61.0–77.0) 68.0 (56.5–75.0) 0.127
Male sex 20 (35) 32 (48) 0.597 (0.289–1.232) 0.163
Associated disease
  Diabetes mellitus 20 (35) 22 (33) 1.105 (0.525–2.330) 0.792
  Heart failure 3 (5) 1 (1) 2.846 (0.326–24.891) 0.344
  Chronic pulmonary disease 1 (2) 1 (1) 1.176 (0.072–19.239) 0.909
  Chronic renal insufficiency 6 (11) 12 (18) 0.561 (0.197–1.595) 0.278
  Liver cirrhosis 1 (2) 2 (3) 0.696 (0.065–7.403) 0.764
  Chemotherapy 8 (14) 22 (33) 0.347 (0.141–0.853) 0.021
  Vascular disease 8 (14) 9 (13) 1.057 (0.379–2.948) 0.915
  Transplantation 3 (5) 3 (4) 1.183 (0.229–6.105) 0.841
  Immunosuppression 3 (5) 3 (4) 1.183 (0.229–6.105) 0.841
  Major surgery 30 d before infection 16 (28) 20 (30) 0.921 (0.423–2.008) 0.837
  Charlson comorbidity index ≥ 2 24 (42) 48 (72) 0.294 (0.139–0.620) 0.001
Device
  Urinary catheter 0 (0) 10 (15) 0.048 (0.002–0.955) 0.047
  Tracheostomy/intubation 0 (0) 2 (3) 0.228 (0.005–9.549) 0.438
  Nasogastric tube 0 (0) 3 (4) 0.16 (0.005–4.998) 0.297
  Any device 0 (0) 11 (16) 0.043 (0.002–0.841) 0.038
Previous antibiotics within last month
  Penicillin 1 (2) 6 (9) 0.251 (0.036–1.734) 0.161
Cephalosporin
  First generation 0 (0) 2 (3) 0.228 (0.005–9.549) 0.438
  Second generation 1 (2) 4 (6) 0.375 (0.048–2.929) 0.350
  Third generation 5 (9) 10 (15) 0.574 (0.185–1.776) 0.335
  Carbapenem 1 (2) 8 (12) 0.186 (0.029–1.201) 0.077
  Fluoroquinolone 1 (2) 9 (13) 0.164 (0.026–1.033) 0.054
  Any antibiotics 9 (16) 35 (52) 0.179 (0.077–0.420) <0.001
Source of infection
  Primary 11 (19) 21 (31) 0.535 (0.232–1.232) 0.142
  Urinary 39 (68) 37 (55) 1.737 (0.831–3.628) 0.142
  Hepatobiliary 5 (9) 5 (7) 1.191 (0.327–4.339) 0.791
  Gastrointestinal 2 (4) 0 (0) 6.074 (0.145–254.296) 0.344
  Respiratory 0 (0) 5 (7) 0.099 (0.004–2.404) 0.155
Polymicrobial infection 4 (7) 8 (12) 0.589 (0.169–2.046) 0.405
ST131 clone 28 (49) 30 (45) 1.188 (0.585–2.411) 0.634
Septic shock/severe sepsis 11 (19) 21 (31) 0.535 (0.232–1.232) 0.142
Pitt bacteremia score ≥ 2 16 (28) 18 (27) 1.064 (0.482–2.346) 0.878
30-day mortality 3 (5) 13 (19) 0.259 (0.073–0.923) 0.037
Table 1. Clinical features of patients with community onset ESBL-producing E. coli bacteremia: Univariate 
Analysis. Data are no. (%) of patients. CA, community-associated; HA, healthcare-associated; OR, odds ratio; 
CI, confidence interval.
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Results
Clinical features of patients with community-onset ESBL-producing E. coli bacteremia. Of 
124 total patients with ESBL-producing E. coli community-onset bacteremia, 57 (46%) had community-associ-
ated bacteremia and the others had healthcare-associated bacteremia. There were fewer patients with a Charlson 
comorbidity index score of 2 or above in the community-associated bacteremia group than in the healthcare-as-
sociated bacteremia group. The mortality rate in patients with community-associated bacteremia (5.3%) was 
lower than that in patients with healthcare-associated bacteremia (22.8%, Table 1). However, no statistical differ-
ence was found between mortality rates of ST131 and non-ST131 (Table 4). Also, there was no statistical differ-
ence between mortality rates of H30Rx subclone and non-ST131 (P = 0.090).
Microbiological Analysis. The antimicrobial susceptibilities of community-onset ESBL–producing E. coli 
were similar between the community-associated and healthcare-associated bacteremia groups, except for the 
results of ceftazidime and aztreonam, which were associated with more resistance in the healthcare-associated bac-
teremia group (Table 2). Globally, epidemic ST131 strains accounted for 49.1% (28/57) of community-associated 
bacteremia cases and 44.8% (30/67) of healthcare-associated bacteremia cases. Of 58 total ST131 strains, nine 
O16-H41 strains were detected, and 61.1% (30/49) of O25-H30 strains had H30Rx (Table 3). The most common 
ESBL genotype was CTX-M-15 (46.0%, 57/124), followed by CTX-M-14 (37.1%, 46/124). PFGE patterns did 
not show a dominant clonality in community-associated or community-onset healthcare-associated bacteremia 
(Fig. 1). Eighteen “Pasteur” sequence type (PST) isolates other than ST131 from community-associated bacte-
remia (based on representative PFGE patterns) were PST3 (n = 3), PST8 (n = 3), PST2 (n = 2), PST594 (n = 2), 
and one each for PST13, PST39, PST44, PST53, PST253, PST478, PST666, and PST unknown by the Pasteur 
MLST scheme. A PBRT was conducted for 16 representative isolates of community-onset ESBL–producing 
E. coli. Among these 16 isolates, only nine succeeded in conjugation. Of the nine isolates, five (two of CA group 
and three of HA group) were positive for IncFIA replicon, two showed positive for IncI1-Iγ, and the rest were 
Antimicrobial agent CA (n = 57) HA (n = 67) OR (95% CI) P value
Ampicillin-sulbactam 46 (81) 54 (81) 1.002 (0.410–2.449) 0.997
Piperacillin-tazobactam 0 (0) 3 (4) 0.160 (0.005–4.998) 0.297
Cefotaxime 55 (96) 67 (100) 0.165 (0.004–6.892) 0.344
Ceftazidime 38 (67) 57 (85) 0.361 (0.152–0.857) 0.021
Cefepime 35 (61) 49 (73) 0.590 (0.276–1.260) 0.173
Meropenem 0 (0) 0 (0) — —
Ertapenem 0 (0) 0 (0) — —
Levofloxacin 42 (74) 53 (79) 0.743 (0.323–1.710) 0.486
Aztreonam 43 (75) 60 (90) 0.372 (0.139–0.994) 0.049
Amikacin 0 (0) 0 (0) — —
Gentamycin 24 (42) 34 (51) 0.710 (0.349–1.446) 0.346
Trimethoprim-sulfamethoxazole 30 (53) 37 (55) 0.902 (0.444–1.832) 0.776
Table 2. Comparison of antimicrobial resistance between CA and HA in the community-onset ESBL–
producing E. coli: Univariate Analysis. Data are no. (%) of resistant isolates. CA, community-associated; HA, 
healthcare-associated; OR, odds ratio; CI, confidence interval.










  Null 0 1 0 0
  H30 22 0 27 0
  H41 0 5 0 3
CTX-M type
  CTX-M-14 6 3 5 2
  CTX-M-15 15 2 15 1
  CTX-M-27 1 1 6 0
  Other CTX-M 0 0 1 0
Susceptibility test to fluoroquinolone
  Resistance 22 2 27 2
  Susceptibility 0 4 0 1
Table 3. Genetic subgroup and result of susceptibility test to fluoroquinolone of the community-onset ESBL–
producing E. coli. Data are no. of resistant isolates. CA, community-associated; HA, healthcare-associated.
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negative for all tested replicons. The two types of replicons almost equally belonged to CA group (n = 3) and HA 
group (n = 4).
Risk factors of acquisition of ST131 in community-onset ESBL-producing E. coli bacteremia. 
According to a univariate analysis, independent risk factors for acquisition of ST131 isolates over non-ST131 iso-
lates were diabetes mellitus (OR, 2.495; 95% CI, 1.162–5.356; P = 0.019), chronic renal insufficiency (OR, 3.317; 
95% CI, 1.116–9.856; P = 0.031), absence of active cancer (OR, 2.740; 95% CI, 1.314–5.682; P = 0.007), absence 
of history of prior chemotherapy (OR, 3.003; 95% CI, 1.222–7.353; P = 0.016), and absence of history of surgery 
(OR, 3.003; 95% CI, 1.222–7.353; P = 0.016) (Table 4). A multivariate analysis showed that diabetes mellitus 
(OR, 2.347; 95% CI, 1.074–5.128; P = 0.032) and absence of prior chemotherapy history (OR, 2.882; 95% CI, 
1.147–7.246; P = 0.024) were significant risk factors for acquisition of ST131 isolates. Antimicrobial susceptibility 
of the community-onset ESBL–producing E. coli appeared similar between the ST131 and non-ST131 bacteremia 
groups, except for the results of levofloxacin, which were associated with more resistance in the ST131 bacteremia 
group (Table 5).
Risk factors ST131 (n = 58)
Non-ST131 
(n = 66) OR (95% CI) P value
Age in years, median (IQR) 73.5 (61.5–80.0) 68.5 (59.0–74.0) 0.057
Male sex 24 (41) 28 (42) 0.959 (0.469–1.961) 0.909
Associated disease
  Diabetes mellitus 26 (45) 16 (24) 2.495 (1.162–5.356) 0.019
  Heart failure 0 (0) 4 (6) 0.119 (0.004–3.174) 0.204
  Chronic pulmonary disease 1 (2) 1 (2) 1.139 (0.070–18.621) 0.928
  Chronic renal insufficiency 13 (22) 5 (8) 3.317 (1.116–9.856) 0.031
  Liver cirrhosis 1 (2) 2 (3) 0.673 (0.063–7.163) 0.743
  Chemotherapy 8 (14) 22 (33) 0.333 (0.136–0.818) 0.016
  Vascular disease 10 (17) 7 (11) 1.718 (0.609–4.844) 0.306
  Transplantation 1 (2) 5 (8) 0.292 (0.040–2.119) 0.223
  Immunosuppression 3 (5) 3 (5) 1.145 (0.222–5.906) 0.872
  Major surgery 30 d before 
infection 11 (19) 25 (38) 0.394 (0.173–0.895) 0.026
  Charlson comorbidity index ≥ 2 30 (52) 42 (64) 0.617 (0.301–1.266) 0.188
Device
  Urinary catheter 5 (9) 5 (8) 1.150 (0.316–4.189) 0.833
  Tracheostomy/intubation 1 (2) 1 (2) 1.139 (0.070–18.621) 0.928
  Nasogastric tube 0 (0) 3 (5) 0.155 (0.005–4.836) 0.288
  Any device 5 (9) 6 (9) 0.957 (0.276–3.315) 0.945
Previous antibiotics within last month
  Penicillin 4 (7) 3 (5) 1.498 (0.322–6.965) 0.606
Cephalosporin
  First generation 1 (2) 1 (2) 1.139 (0.070–18.621) 0.928
  Second generation 1 (2) 4 (6) 0.363 (0.046–2.832) 0.335
  Third generation 8 (14) 7 (11) 1.335 (0.453–3.940) 0.600
  Carbapenem 3 (5) 6 (9) 0.587 (0.142–2.422) 0.461
  Fluoroquinolone 2 (3) 8 (12) 0.305 (0.066–1.398) 0.126
  Any antibiotics 18 (31) 26 (39) 0.698 (0.332–1.468) 0.344
Source of infection
  Primary 12 (21) 20 (30) 0.610 (0.268–1.389) 0.239
  Urinary 40 (69) 36 (55) 1.829 (0.875–3.823) 0.108
  Hepatobiliary 6 (10) 4 (6) 1.720 (0.463–6.398) 0.418
  Gastrointestinal 0 (0) 2 (3) 0.221 (0.005–9.242) 0.428
  Respiratory 0 (0) 4 (6) 0.119 (0.004–3.174) 0.204
Polymicrobial infection 5 (9) 7 (11) 0.815 (0.245–2.718) 0.740
CA 28 (48) 29 (44) 1.188 (0.585–2.411) 0.634
Septic shock/severe sepsis 16 (28) 16 (24) 1.188 (0.531–2.658) 0.675
Pitt bacteremia score ≥ 2 12 (21) 22 (33) 0.532 (0.236–1.200) 0.128
30-day mortality 4 (7) 12 (18) 0.360 (0.111–1.163) 0.088
Table 4. Risk factors of acquisition of ST131 in community-onset ESBL-producing E. coli bacteremia: 
Univariate Analysis. Data are no. (%) of patients. CA, community-associated; OR, odds ratio; CI, confidence 
interval.
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Risk factors of acquisition of H30Rx subclone in community-onset ESBL-producing E. coli 
bacteremia. Based on univariate analysis, independent risk factors for acquisition of H30Rx subclone over 
non-ST131 isolates were diabetes mellitus (OR, 4.33; 95% CI, 1.77–10.99; P = 0.002), chronic renal insufficiency 
(OR, 4.99; 95% CI, 1.55–17.80; P = 0.009), absence of active cancer (OR, 3.33; 95% CI, 1.37–8.33; P = 0.010), and 
absence of surgical history (OR, 4.17; 95% CI, 1.41–14.29; P = 0.017). Multivariate analysis indicated no signifi-
cant risk factors for acquisition of H30Rx subclone.
Discussion
We have already reported that independent risk factors of community-onset ESBL-producing E. coli bacteremia 
are healthcare-associated infection, malignancy, urinary tract infection, hepatobiliary tract infection, third gener-
ation cephalosporin usage during the preceding three months, and severe sepsis/septic shock9. The most common 
types of ESBL causing community-onset bacteremia were CTX-M-15 and CTX-M-14, and the most commonly 
defined sequence type (ST) was ST131 (11/60, 18.3%) during the study period (from 2005 to 2009)9.
In this study, recent epidemiology (observed between 2013 and 2014) changed with a remarkable increase 
of ST131 in community-onset bacteremia (from 18.3 to 46.8%). A recent dramatic increase of ST131 has been 
reported worldwide, causing serious concern20,21. This epidemiologic shift explains the recent increase of 
community-onset bacteremia in that the ST131-O25-H30 subclone is associated with persistent infections and 
later adverse outcomes, which are independent of multidrug resistance and the association with compromised 
hosts20. Although this earlier study differed in its study population compared to our study (community-onset 
urinary tract infection in the majority vs. community-onset bacteremia only), it supports the hypothesis that H30 
has distinctive properties that allow it to evade host defenses and cause delayed complications20.
In this study, the H30Rx subclone was prevalent as ST131-O25-H30 (61.1%, 30/49), and O16-H41 strains 
were not negligible (15.5% of the total ST131 strains). Serotype O16 was assigned to ST131 by the Achtman 
MLST scheme, but was distinct from the classic ST131-O25 that has resistance to ampicillin, gentamicin, and 
trimethoprim-sulfamethoxazole, and showed susceptibility to fluoroquinolones and extended-spectrum ceph-
alosporin13. This study suggests that ST131 isolates show more multidrug resistance patterns than non-ST131 
isolates. A recent multicenter surveillance study of Korea reported the similar result, although the resistance rate 
to piperacillin-tazobactam was much higher than that seen in our results7. The single, rapidly expanding ST131 
subclone H30-Rx, which is strongly associated with fluoroquinolone resistance and CTX-M-15 ESBL, is the most 
resistant ST131 strain14. The spread of the O16 and H30Rx clones in the Korean community could be important 
for transmission prevention-based control strategies because of their resistance to effective antibiotics.
PFGE patterns did not show a dominant clone for community-associated or healthcare-associated bacteremia, 
and PSTs were also varied by the Pasteur MLST scheme. IncFIA and IncI1-Iγ replicons were distributed evenly 
in community-associated and healthcare-associated bacteremia. This is suggestive of multiple evolutionary pro-
cesses in the extraintestinal E. coli community in the course of the emergence of dominant ST131 clones.
Many studies on risk factors for ST131 have been reported worldwide since 201322–25. However, despite the 
high incidence of E. coli ST131 ESBLs in Korea, the characteristics have rarely been investigated. We investi-
gated risk factors for acquisition of ST131 in patients with community-onset ESBL-producing E. coli causing 
bloodstream infections, and we adjusted confounding variables such as severity of underlying disease, and 
co-morbidities. Although diabetes mellitus and absence of prior chemotherapy history were significantly associ-
ated with acquisition of ST131 clones, in the present study, other underlying disease and co-morbidities were sim-
ilar between the ST131 group and the non-ST131 group. These results suggest that E. coli ST131 strains producing 
ESBLs have disseminated in both the community and in hospitals in Korea. Previous studies investigated the 
risk factors for colonization or infection caused by isolates of ST131 E. coli22–26. According to such studies, there 
were many risk factors for acquisition of ST131 E. coli such as recent surgery, unknown source of bacteremia, old 





(n = 66) OR (95% CI) P value
Ampicillin-sulbactam 50 (86) 50 (76) 1.941 (0.765–4.925) 0.163
Piperacillin-tazobactam 2 (3) 1 (2) 1.933 (0.182–20.565) 0.585
Cefotaxime 58 (100) 64 (97) 4.531 (0.108–189.767) 0.428
Ceftazidime 46 (79) 49 (74) 1.315 (0.567–3.048) 0.523
Cefepime 41 (71) 43 (65) 1.281 (0.600–2.735) 0.522
Meropenem 0 (0) 0 (0) — —
Ertapenem 0 (0) 0 (0) — —
Levofloxacin 53 (91) 42 (64) 5.608 (2.014–15.616) 0.001
Aztreonam 49 (84) 54 (82) 1.195 (0.464–3.077) 0.712
Amikacin 0 (0) 0 (0) — —
Gentamycin 29 (50) 29 (44) 1.271 (0.626–2.580) 0.507
Trimethoprim-sulfamethoxazole 28 (48) 39 (59) 0.651 (0.319–1.325) 0.236
Table 5. Comparison of antimicrobial resistance between ST131 and non-ST131 in the community-onset 
ESBL–producing E. coli: Univariate Analysis. Data are no. (%) of resistant isolates. OR, odds ratio; CI, 
confidence interval.
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previous receipt of extended-spectrum cephalosporins and macrolides or fluoroquinolones, female gender, dia-
betes mellitus, bedridden status, secondary bacteremia, and nonuse of urinary catheter. Risk factors were different 
in each study, including the current study. Our interpretation is that the markedly different population in each 
study caused the difference in risk factors for acquisition of ST131 E. coli. There are some limitations in this study 
in that it was conducted at a single university hospital; therefore the results cannot be generalized to community 
hospitals and other university hospitals with different settings. Although community-onset healthcare-associated 
bacteremia group included patients with records of previous hospitalization (within the last 3–6 months) and 
residency at long-term care facilities, we did not analyze them separately.
In conclusion, a considerable proportion of community-onset ESBL-producing E. coli bacteremia was 
observed. ST131 clones appear to be associated with the spread of community-associated bacteremia exhibit-
ing high antimicrobial resistance and highly virulent H30Rx traits, which could become a major public health 
concern in Korea. The potential spread of ESBL-producing E. coli causing blood stream infections is a chal-
lenge for the management of community-associated infections, so this study could be informative regarding 
current molecular epidemiologic shifts in community-onset bacteremia and could lead to better infection control 
strategies.
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